Nuvectra?

Quote
anonymous said:
Because they all want to come to BSX where we get things done. ‘18 is going be our best year yet! No where else to go once you leave the primitive offerings of SJM, MDT and NVR. Come to the future over here, we would love to have you be a part of our success!!
Click to expand...

sign me up. revision of these drg leads are,,,,
 












anonymous said:
Because they all want to come to BSX where we get things done. ‘18 is going be our best year yet! No where else to go once you leave the primitive offerings of SJM, MDT and NVR. Come to the future over here, we would love to have you be a part of our success!!
Click to expand...

Amazing sentiment from the pimary market share donor over the last 2 years.
 






anonymous said:
Because they all want to come to BSX where we get things done. ‘18 is going be our best year yet! No where else to go once you leave the primitive offerings of SJM, MDT and NVR. Come to the future over here, we would love to have you be a part of our success!!
Click to expand...

You must have drank all the corporate koolaid. I’m with BSX, I don’t buy into their lies and believe in shit like Prism and our “finally launched “ single cell suck the life out of that IPG battery, but at least the splinters are basically gone.
 


















anonymous said:
We're riding the Wave because we are WINNERS!
Click to expand...


Nuvectra™ Reports Fourth Quarter and Full Year 2017 Financial Results

PLANO, Texas, March 06, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NVTR), a neurostimulation medical device company, today announced financial results for the fourth quarter and full year ended December 31, 2017.
  • Reported record consolidated revenues of $12.0 million for the fourth quarter 2017 and $31.8 million for the full year 2017.
  • Achieved the 1,000th Algovita® SCS System implantation in U.S. in December 2017.
  • Completed follow-on public offering of common stock for gross proceeds of approximately $26.0 million in February 2018
Scott Drees, CEO, said, “In 2017, our first full commercial year, we demonstrated our ability to compete in the SCS market, delivering over $10 million in Q4 Algovita revenue. As we move into 2018, we expect to continue growing our SCS market share by demonstrating the clinical benefits of our Algovita system through clinical studies, obtaining MRI approvals, and building physician awareness of the benefits of the Algovita system. We also anticipate CE mark approval in the second quarter of 2018 of the Virtis sacral neuromodulation system (SNM), and are on track for FDA approval, with the expectation of a commercial launch in the United States in the second half of 2018.”
 




































Top Bottom
Back
Quote